AtriCure Inc. (ATRC)
| Bid | 34.28 |
| Market Cap | 1.73B |
| Revenue (ttm) | 499.95M |
| Net Income (ttm) | -36.36M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -46.41 |
| Forward PE | -155.86 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 36 |
| Volume | 205,332 |
| Avg. Volume (20D) | 507,777 |
| Open | 34.60 |
| Previous Close | 34.29 |
| Day's Range | 34.51 - 35.66 |
| 52-Week Range | 25.57 - 43.11 |
| Beta | 1.59 |
| Ex-Dividend Date | n/a |
About ATRC
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ATRC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
AtriCure to Participate in the 2025 Wells Fargo Healthcare ConferenceMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
2 months ago · fool.com
AtriCure (ATRC) Q2 Revenue Jumps 17%AtriCure (ATRC) Q2 Revenue Jumps 17%
2 months ago · businesswire.com
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth ConferenceMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
2 months ago · businesswire.com
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke PreventionMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...
